Navigation Links
Spherix D-tagatose to be Supplied by Inalco SpA

BETHESDA, Md., April 30 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) announced today that it has signed letters of intent with Inalco SpA, an Italy-based manufacturer of bulk pharmaceutical ingredients, to supply a portion of the D-tagatose used in the Spherix Phase 3 clinical trial of the unique sugar as a treatment for Type 2 diabetes. Inalco will also provide cGMP (current Good Manufacturing Practice) production batches of D- tagatose for the Spherix New Drug Application (NDA) and will hold a Drug Master File (DMF). The Phase 3 clinical trial is scheduled to be completed at the end of 2009. If the clinical trial demonstrates efficacy of D-tagatose as a treatment for Type 2 diabetes, Spherix plans an initial purchase of 100 metric tons of D-tagatose from Inalco and a long-term supply agreement. Financial terms were not disclosed.

"This is a significant accomplishment toward achieving our goal of putting in place all the elements needed for a complete NDA submission," said Claire Kruger, CEO of Spherix.

Spherix is currently seeking approval from the US Food and Drug Administration (FDA) in order to market D-tagatose nationwide as a drug. If granted US approval of its NDA, Spherix plans to also apply for approval of D-tagatose to treat diabetes in the European Union (EU).

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is

SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Growth Achieved in Spherixs Health Sciences Consulting Business
2. Spherix Reports Second Quarter Earnings
Post Your Comments:
(Date:11/26/2015)... --> --> Juntendo University ... contrast weighting of MRI for patients with Multiple Sclerosis ... agreement with SyntheticMR in order to use SyMRI in clinical ... to generate multiple contrast images from a single scan and ... making it possible to both fine tune images and recreate ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
Breaking Medicine Technology:
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... people across the country to celebrate their sobriety and show through pictures what ... “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, ...
(Date:11/25/2015)... ... 2015 , ... On November 23rd 2015 Cozy Products, a division ... business. Cozy Products explains what this means for business moving forward. , The Tri ... Products business model: to sell personal heaters that reduce energy consumption, are economical and ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by ... Chicago, IL, UV Angel is evaluating the efficacy of its product and its disinfection ... (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic ...
Breaking Medicine News(10 mins):